1
|
Giannelli SG, Luoni M, Iannielli A, Middeldorp J, Philippens I, Bido S, Körbelin J, Broccoli V. New AAV9 engineered variants with enhanced neurotropism and reduced liver off-targeting in mice and marmosets. iScience 2024; 27:109777. [PMID: 38711458 PMCID: PMC11070337 DOI: 10.1016/j.isci.2024.109777] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Revised: 02/28/2024] [Accepted: 04/15/2024] [Indexed: 05/08/2024] Open
Abstract
Although adeno-associated virus 9 (AAV9) has been highly exploited as delivery platform for gene-based therapies, its efficacy is hampered by low efficiency in crossing the adult blood-brain barrier (BBB) and pronounced targeting to the liver upon intravenous delivery. We generated a new galactose binding-deficient AAV9 peptide display library and selected two new AAV9 engineered capsids with enhanced targeting in mouse and marmoset brains after intravenous delivery. Interestingly, the loss of galactose binding greatly reduced undesired targeting to peripheral organs, particularly the liver, while not compromising transduction of the brain vasculature. However, the galactose binding was necessary to efficiently infect non-endothelial brain cells. Thus, the combinatorial actions of the galactose-binding domain and the incorporated displayed peptide are crucial to enhance BBB crossing along with brain cell transduction. This study describes two novel capsids with high brain endothelial infectivity and extremely low liver targeting based on manipulating the AAV9 galactose-binding domain.
Collapse
Affiliation(s)
- Serena Gea Giannelli
- Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Mirko Luoni
- Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- CNR Institute of Neuroscience, 20854 Vedano al Lambro, Italy
| | - Angelo Iannielli
- Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- CNR Institute of Neuroscience, 20854 Vedano al Lambro, Italy
| | - Jinte Middeldorp
- Biomedical Primate Research Centre (BPRC), 2288 GJ Rijswijk, the Netherlands
| | - Ingrid Philippens
- Biomedical Primate Research Centre (BPRC), 2288 GJ Rijswijk, the Netherlands
| | - Simone Bido
- Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Jakob Körbelin
- Department of Oncology, Hematology and Bone Marrow Transplantation, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Vania Broccoli
- Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- CNR Institute of Neuroscience, 20854 Vedano al Lambro, Italy
| |
Collapse
|
2
|
Maimaitili M, Chen M, Febbraro F, Ucuncu E, Kelly R, Niclis JC, Christiansen JR, Mermet-Joret N, Niculescu D, Lauritsen J, Iannielli A, Klæstrup IH, Jensen UB, Qvist P, Nabavi S, Broccoli V, Nykjær A, Romero-Ramos M, Denham M. Enhanced production of mesencephalic dopaminergic neurons from lineage-restricted human undifferentiated stem cells. Nat Commun 2023; 14:7871. [PMID: 38052784 DOI: 10.1038/s41467-023-43471-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Accepted: 11/10/2023] [Indexed: 12/07/2023] Open
Abstract
Current differentiation protocols for generating mesencephalic dopaminergic (mesDA) neurons from human pluripotent stem cells result in grafts containing only a small proportion of mesDA neurons when transplanted in vivo. In this study, we develop lineage-restricted undifferentiated stem cells (LR-USCs) from pluripotent stem cells, which enhances their potential for differentiating into caudal midbrain floor plate progenitors and mesDA neurons. Using a ventral midbrain protocol, 69% of LR-USCs become bona fide caudal midbrain floor plate progenitors, compared to only 25% of human embryonic stem cells (hESCs). Importantly, LR-USCs generate significantly more mesDA neurons under midbrain and hindbrain conditions in vitro and in vivo. We demonstrate that midbrain-patterned LR-USC progenitors transplanted into 6-hydroxydopamine-lesioned rats restore function in a clinically relevant non-pharmacological behavioral test, whereas midbrain-patterned hESC-derived progenitors do not. This strategy demonstrates how lineage restriction can prevent the development of undesirable lineages and enhance the conditions necessary for mesDA neuron generation.
Collapse
Affiliation(s)
- Muyesier Maimaitili
- Danish Research Institute of Translational Neuroscience (DANDRITE), Nordic EMBL Partnership for Molecular Medicine, Aarhus University, 8000C, Aarhus, Denmark
- Department of Biomedicine, Aarhus University, 8000C, Aarhus, Denmark
| | - Muwan Chen
- Danish Research Institute of Translational Neuroscience (DANDRITE), Nordic EMBL Partnership for Molecular Medicine, Aarhus University, 8000C, Aarhus, Denmark
- Department of Biomedicine, Aarhus University, 8000C, Aarhus, Denmark
| | - Fabia Febbraro
- Department of Biomedicine, Aarhus University, 8000C, Aarhus, Denmark
- Department of Clinical Genetics, Aarhus University Hospital, 8200, Aarhus, Denmark
| | - Ekin Ucuncu
- Danish Research Institute of Translational Neuroscience (DANDRITE), Nordic EMBL Partnership for Molecular Medicine, Aarhus University, 8000C, Aarhus, Denmark
- Department of Biomedicine, Aarhus University, 8000C, Aarhus, Denmark
| | - Rachel Kelly
- Danish Research Institute of Translational Neuroscience (DANDRITE), Nordic EMBL Partnership for Molecular Medicine, Aarhus University, 8000C, Aarhus, Denmark
- Department of Biomedicine, Aarhus University, 8000C, Aarhus, Denmark
| | | | | | - Noëmie Mermet-Joret
- Danish Research Institute of Translational Neuroscience (DANDRITE), Nordic EMBL Partnership for Molecular Medicine, Aarhus University, 8000C, Aarhus, Denmark
- Department of Molecular Biology and Genetics, Aarhus University, 8000C, Aarhus, Denmark
- Center of Excellence PROMEMO, Aarhus University, Aarhus, Denmark
| | - Dragos Niculescu
- Danish Research Institute of Translational Neuroscience (DANDRITE), Nordic EMBL Partnership for Molecular Medicine, Aarhus University, 8000C, Aarhus, Denmark
- Department of Biomedicine, Aarhus University, 8000C, Aarhus, Denmark
- Center of Excellence PROMEMO, Aarhus University, Aarhus, Denmark
| | - Johanne Lauritsen
- Danish Research Institute of Translational Neuroscience (DANDRITE), Nordic EMBL Partnership for Molecular Medicine, Aarhus University, 8000C, Aarhus, Denmark
- Department of Biomedicine, Aarhus University, 8000C, Aarhus, Denmark
| | - Angelo Iannielli
- Stem Cell and Neurogenesis Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132, Milan, Italy
- CNR Institute of Neuroscience, 20129, Milan, Italy
| | - Ida H Klæstrup
- Danish Research Institute of Translational Neuroscience (DANDRITE), Nordic EMBL Partnership for Molecular Medicine, Aarhus University, 8000C, Aarhus, Denmark
- Department of Biomedicine, Aarhus University, 8000C, Aarhus, Denmark
| | - Uffe Birk Jensen
- Department of Biomedicine, Aarhus University, 8000C, Aarhus, Denmark
- Department of Clinical Genetics, Aarhus University Hospital, 8200, Aarhus, Denmark
| | - Per Qvist
- Department of Biomedicine, Aarhus University, 8000C, Aarhus, Denmark
- Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, 8000C, Aarhus, Denmark
- Centre for Integrative Sequencing, iSEQ, Aarhus University, 8000C, Aarhus, Denmark
- Centre for Genomics and Personalized Medicine, CGPM, Aarhus University, 8000C, Aarhus, Denmark
| | - Sadegh Nabavi
- Danish Research Institute of Translational Neuroscience (DANDRITE), Nordic EMBL Partnership for Molecular Medicine, Aarhus University, 8000C, Aarhus, Denmark
- Department of Molecular Biology and Genetics, Aarhus University, 8000C, Aarhus, Denmark
- Center of Excellence PROMEMO, Aarhus University, Aarhus, Denmark
| | - Vania Broccoli
- Stem Cell and Neurogenesis Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132, Milan, Italy
- CNR Institute of Neuroscience, 20129, Milan, Italy
| | - Anders Nykjær
- Danish Research Institute of Translational Neuroscience (DANDRITE), Nordic EMBL Partnership for Molecular Medicine, Aarhus University, 8000C, Aarhus, Denmark
- Department of Biomedicine, Aarhus University, 8000C, Aarhus, Denmark
- Center of Excellence PROMEMO, Aarhus University, Aarhus, Denmark
| | - Marina Romero-Ramos
- Danish Research Institute of Translational Neuroscience (DANDRITE), Nordic EMBL Partnership for Molecular Medicine, Aarhus University, 8000C, Aarhus, Denmark
- Department of Biomedicine, Aarhus University, 8000C, Aarhus, Denmark
| | - Mark Denham
- Danish Research Institute of Translational Neuroscience (DANDRITE), Nordic EMBL Partnership for Molecular Medicine, Aarhus University, 8000C, Aarhus, Denmark.
- Department of Biomedicine, Aarhus University, 8000C, Aarhus, Denmark.
| |
Collapse
|
3
|
Pedrini M, Iannielli A, Meneghelli L, Passarella D, Broccoli V, Seneci P. Synthesis and Preliminary Characterization of Putative Anle138b-Centered PROTACs against α-Synuclein Aggregation. Pharmaceutics 2023; 15:pharmaceutics15051467. [PMID: 37242709 DOI: 10.3390/pharmaceutics15051467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2023] [Revised: 04/29/2023] [Accepted: 05/09/2023] [Indexed: 05/28/2023] Open
Abstract
The search for disease-modifying agents targeted against Parkinson's disease led us to rationally design a small array of six Anle138b-centered PROTACs, 7a,b, 8a,b and 9a,b, targeting αSynuclein (αSyn) aggregates for binding, polyubiquitination by the E3 ligase Cereblon (CRBN), and proteasomal degradation. Lenalidomide and thalidomide were used as CRBN ligands and coupled with amino- and azido Anle138b derivatives through flexible linkers and coupling reactions (amidation, 'click' chemistry). Four Anle138b-PROTACs, 8a,b and 9a,b, were characterized against in vitro αSyn aggregation, monitoring them in a Thioflavin T (ThT) fluorescence assay and in dopaminergic neurons derived from a set of isogenic pluripotent stem cell (iPSC) lines with SNCA multiplications. Native and seeded αSyn aggregation was determined with a new biosensor, and a partial correlation between αSyn aggregation, cellular dysfunctions, and neuronal survival was obtained. Anle138b-PROTAC 8a was characterized as the most promising αSyn aggregation inhibitor/degradation inducer, with potential usefulness against synucleinopathies and cancer.
Collapse
Affiliation(s)
- Martina Pedrini
- Chemistry Department, Milan University, Via Golgi 19, 20133 Milan, Italy
| | - Angelo Iannielli
- Neuroscience Institute, Consiglio Nazionale delle Ricerche (CNR), Via Olgettina 58, 20132 Milan, Italy
- Stem Cells and Neurogenesis Unit, San Raffaele Hospital, Via Olgettina 58, 20132 Milan, Italy
| | - Lorenzo Meneghelli
- Chemistry Department, Milan University, Via Golgi 19, 20133 Milan, Italy
| | - Daniele Passarella
- Chemistry Department, Milan University, Via Golgi 19, 20133 Milan, Italy
| | - Vania Broccoli
- Neuroscience Institute, Consiglio Nazionale delle Ricerche (CNR), Via Olgettina 58, 20132 Milan, Italy
- Stem Cells and Neurogenesis Unit, San Raffaele Hospital, Via Olgettina 58, 20132 Milan, Italy
| | - Pierfausto Seneci
- Chemistry Department, Milan University, Via Golgi 19, 20133 Milan, Italy
| |
Collapse
|
4
|
Rossi G, Ordazzo G, Vanni NN, Castoldi V, Iannielli A, Di Silvestre D, Bellini E, Bernardo L, Giannelli SG, Luoni M, Muggeo S, Leocani L, Mauri P, Broccoli V. MCT1-dependent energetic failure and neuroinflammation underlie optic nerve degeneration in Wolfram syndrome mice. eLife 2023; 12:81779. [PMID: 36645345 PMCID: PMC9891717 DOI: 10.7554/elife.81779] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Accepted: 01/13/2023] [Indexed: 01/17/2023] Open
Abstract
Wolfram syndrome 1 (WS1) is a rare genetic disorder caused by mutations in the WFS1 gene leading to a wide spectrum of clinical dysfunctions, among which blindness, diabetes, and neurological deficits are the most prominent. WFS1 encodes for the endoplasmic reticulum (ER) resident transmembrane protein wolframin with multiple functions in ER processes. However, the WFS1-dependent etiopathology in retinal cells is unknown. Herein, we showed that Wfs1 mutant mice developed early retinal electrophysiological impairments followed by marked visual loss. Interestingly, axons and myelin disruption in the optic nerve preceded the degeneration of the retinal ganglion cell bodies in the retina. Transcriptomics at pre-degenerative stage revealed the STAT3-dependent activation of proinflammatory glial markers with reduction of the homeostatic and pro-survival factors glutamine synthetase and BDNF. Furthermore, label-free comparative proteomics identified a significant reduction of the monocarboxylate transport isoform 1 (MCT1) and its partner basigin that are highly enriched on retinal glia and myelin-forming oligodendrocytes in optic nerve together with wolframin. Loss of MCT1 caused a failure in lactate transfer from glial to neuronal cell bodies and axons leading to a chronic hypometabolic state. Thus, this bioenergetic impairment is occurring concurrently both within the axonal regions and cell bodies of the retinal ganglion cells, selectively endangering their survival while impacting less on other retinal cells. This metabolic dysfunction occurs months before the frank RGC degeneration suggesting an extended time-window for intervening with new therapeutic strategies focused on boosting retinal and optic nerve bioenergetics in WS1.
Collapse
Affiliation(s)
- Greta Rossi
- Division of Neuroscience, San Raffaele Scientific InstituteMilanoItaly
| | - Gabriele Ordazzo
- Division of Neuroscience, San Raffaele Scientific InstituteMilanoItaly
| | - Niccolò N Vanni
- Division of Neuroscience, San Raffaele Scientific InstituteMilanoItaly
| | - Valerio Castoldi
- Division of Neuroscience, San Raffaele Scientific InstituteMilanoItaly
- Experimental Neurophysiology Unit, Institute of Experimental Neurology (INSPE), San Raffaele Scientific InstituteMilanItaly
| | - Angelo Iannielli
- Division of Neuroscience, San Raffaele Scientific InstituteMilanoItaly
- National Research Council of Italy, Institute of NeuroscienceMilanoItaly
| | - Dario Di Silvestre
- National Research Council of Italy, Institute of Technologies in BiomedicineMilanItaly
| | - Edoardo Bellini
- Division of Neuroscience, San Raffaele Scientific InstituteMilanoItaly
| | - Letizia Bernardo
- National Research Council of Italy, Institute of Technologies in BiomedicineMilanItaly
| | | | - Mirko Luoni
- Division of Neuroscience, San Raffaele Scientific InstituteMilanoItaly
- National Research Council of Italy, Institute of NeuroscienceMilanoItaly
| | - Sharon Muggeo
- Division of Neuroscience, San Raffaele Scientific InstituteMilanoItaly
| | - Letizia Leocani
- Division of Neuroscience, San Raffaele Scientific InstituteMilanoItaly
- Experimental Neurophysiology Unit, Institute of Experimental Neurology (INSPE), San Raffaele Scientific InstituteMilanItaly
| | - PierLuigi Mauri
- National Research Council of Italy, Institute of Technologies in BiomedicineMilanItaly
| | - Vania Broccoli
- Division of Neuroscience, San Raffaele Scientific InstituteMilanoItaly
- National Research Council of Italy, Institute of NeuroscienceMilanoItaly
| |
Collapse
|
5
|
Iannielli A, Luoni M, Giannelli SG, Ferese R, Ordazzo G, Fossati M, Raimondi A, Opazo F, Corti O, Prehn JHM, Gambardella S, Melki R, Broccoli V. Modeling native and seeded Synuclein aggregation and related cellular dysfunctions in dopaminergic neurons derived by a new set of isogenic iPSC lines with SNCA multiplications. Cell Death Dis 2022; 13:881. [PMID: 36261424 PMCID: PMC9581971 DOI: 10.1038/s41419-022-05330-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2022] [Revised: 10/02/2022] [Accepted: 10/07/2022] [Indexed: 11/05/2022]
Abstract
Triplication of the SNCA gene, encoding the protein alpha-Synuclein (αSyn), is a rare cause of aggressive and early-onset parkinsonism. Herein, we generated iPSCs from two siblings with a recently described compact SNCA gene triplication and suffering from severe motor impairments, psychiatric symptoms, and cognitive deterioration. Using CRISPR/Cas9 gene editing, each SNCA copy was inactivated by targeted indel mutations generating a panel of isogenic iPSCs with a decremental number from 4 down to none of functional SNCA gene alleles. We differentiated these iPSC lines in midbrain dopaminergic (DA) neuronal cultures to characterize αSyn aggregation in native and seeded conditions and evaluate its associated cellular dysfunctions. Utilizing a new nanobody-based biosensor combined with super-resolved imaging, we were able to visualize and measure αSyn aggregates in early DA neurons in unstimulated conditions. Calcium dysregulation and mitochondrial alterations were the first pathological signs detectable in early differentiated DA neuronal cultures. Accelerated αSyn aggregation was induced by exposing neurons to structurally well-characterized synthetic αSyn fibrils. 4xSNCA DA neurons showed the highest vulnerability, which was associated with high levels of oxidized DA and amplified by TAX1BP1 gene disruption. Seeded DA neurons developed large αSyn deposits whose morphology and internal constituents resembled Lewy bodies commonly observed in Parkinson's disease (PD) patient brain tissues. These findings provide strong evidence that this isogenic panel of iPSCs with SNCA multiplications offers a remarkable cellular platform to investigate mechanisms of PD and validate candidate inhibitors of native and seeded αSyn aggregation.
Collapse
Affiliation(s)
- Angelo Iannielli
- grid.5326.20000 0001 1940 4177National Research Council (CNR), Institute of Neuroscience, 20129 Milan, Italy ,grid.18887.3e0000000417581884Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Mirko Luoni
- grid.18887.3e0000000417581884Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Serena Gea Giannelli
- grid.18887.3e0000000417581884Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
| | | | - Gabriele Ordazzo
- grid.18887.3e0000000417581884Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Matteo Fossati
- grid.5326.20000 0001 1940 4177National Research Council (CNR), Institute of Neuroscience, 20129 Milan, Italy ,grid.417728.f0000 0004 1756 8807IRCCS Humanitas Research Hospital, via Manzoni 56, 20089 Rozzano Milan, Italy
| | - Andrea Raimondi
- grid.18887.3e0000000417581884Experimental Imaging Center, San Raffaele Scientific Institute, Milan, Italy
| | - Felipe Opazo
- grid.411984.10000 0001 0482 5331University Medical Center Göttingen, D-37073 Göttingen, Germany
| | - Olga Corti
- grid.425274.20000 0004 0620 5939Sorbonne Université, Institut du Cerveau (ICM), Inserm U1127, CNRS, UMR 7225 Paris, France
| | - Jochen H. M. Prehn
- grid.4912.e0000 0004 0488 7120Royal College of Surgeons in Ireland University of Medicine and Health Sciences, Department of Physiology and Medical Physics and SFI FutureNeuro Research Centre, 123 St. Stephen’s Green, Dublin, Ireland
| | - Stefano Gambardella
- grid.419543.e0000 0004 1760 3561IRCCS Neuromed, Pozzilli, Italy ,grid.12711.340000 0001 2369 7670Department of Biomolecular Sciences, University of Urbino “Carlo Bo,, Urbino, Italy
| | - Ronald Melki
- grid.460789.40000 0004 4910 6535Institut Francois Jacob, Molecular Imaging Center (MIRCen), Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA) and Centre National de la Recherche Scientifique (CNRS), Université Paris-Saclay, Fontenay-aux-Roses, France
| | - Vania Broccoli
- grid.5326.20000 0001 1940 4177National Research Council (CNR), Institute of Neuroscience, 20129 Milan, Italy ,grid.18887.3e0000000417581884Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
| |
Collapse
|
6
|
Palombo F, Peron C, Caporali L, Iannielli A, Maresca A, Di Meo I, Fiorini C, Segnali A, Sciacca FL, Rizzo A, Levi S, Suomalainen A, Prigione A, Broccoli V, Carelli V, Tiranti V. The relevance of mitochondrial DNA variants fluctuation during reprogramming and neuronal differentiation of human iPSCs. Stem Cell Reports 2021; 16:1953-1967. [PMID: 34329598 PMCID: PMC8365099 DOI: 10.1016/j.stemcr.2021.06.016] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2021] [Revised: 06/25/2021] [Accepted: 06/26/2021] [Indexed: 12/18/2022] Open
Abstract
The generation of inducible pluripotent stem cells (iPSCs) is a revolutionary technique allowing production of pluripotent patient-specific cell lines used for disease modeling, drug screening, and cell therapy. Integrity of nuclear DNA (nDNA) is mandatory to allow iPSCs utilization, while quality control of mitochondrial DNA (mtDNA) is rarely included in the iPSCs validation process. In this study, we performed mtDNA deep sequencing during the transition from parental fibroblasts to reprogrammed iPSC and to differentiated neuronal precursor cells (NPCs) obtained from controls and patients affected by mitochondrial disorders. At each step, mtDNA variants, including those potentially pathogenic, fluctuate between emerging and disappearing, and some having functional implications. We strongly recommend including mtDNA analysis as an unavoidable assay to obtain fully certified usable iPSCs and NPCs. mtDNA deep sequencing is mandatory in quality control of iPSCs mtDNA variants fluctuate at each step from fibroblasts/PBMC, to iPSCs and NPCs mtDNA variants greatly affect iPSC phenotype, reflecting their healthiness Results could be misinterpreted if mtDNA variants presence has not been assessed
Collapse
Affiliation(s)
- Flavia Palombo
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Programma di Neurogenetica, Bologna 40139, Italy
| | - Camille Peron
- Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan 20133, Italy
| | - Leonardo Caporali
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Programma di Neurogenetica, Bologna 40139, Italy
| | - Angelo Iannielli
- Division of Neuroscience, San Raffaele Scientific Institute, Milan 20132, Italy
| | - Alessandra Maresca
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Programma di Neurogenetica, Bologna 40139, Italy
| | - Ivano Di Meo
- Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan 20133, Italy
| | - Claudio Fiorini
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Programma di Neurogenetica, Bologna 40139, Italy; Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Bologna 40123, Italy
| | - Alice Segnali
- Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan 20133, Italy
| | | | - Ambra Rizzo
- Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan 20133, Italy
| | - Sonia Levi
- Division of Neuroscience, San Raffaele Scientific Institute, Milan 20132, Italy; Vita-Salute San Raffaele University, Milan 20132, Italy
| | - Anu Suomalainen
- Stem Cell and Metabolism Research Program Unit, Faculty of Medicine, University of Helsinki, Helsinki 00014, Finland; Neuroscience Institute, HiLife, University of Helsinki, Helsinki 00014, Finland; HUSLab, Helsinki University Hospital, Helsinki 00014, Finland
| | - Alessandro Prigione
- Department of General Pediatrics, Neonatology and Pediatric Cardiology, Duesseldorf University Hospital, Medical Faculty, Heinrich Heine University, Duesseldorf 40225, Germany
| | - Vania Broccoli
- Division of Neuroscience, San Raffaele Scientific Institute, Milan 20132, Italy; National Research Council (CNR), Institute of Neuroscience, Milan 20132, Italy
| | - Valerio Carelli
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Programma di Neurogenetica, Bologna 40139, Italy; Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Bologna 40123, Italy
| | - Valeria Tiranti
- Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan 20133, Italy.
| |
Collapse
|
7
|
Peron C, Maresca A, Cavaliere A, Iannielli A, Broccoli V, Carelli V, Di Meo I, Tiranti V. Exploiting hiPSCs in Leber's Hereditary Optic Neuropathy (LHON): Present Achievements and Future Perspectives. Front Neurol 2021; 12:648916. [PMID: 34168607 PMCID: PMC8217617 DOI: 10.3389/fneur.2021.648916] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2021] [Accepted: 04/26/2021] [Indexed: 01/19/2023] Open
Abstract
More than 30 years after discovering Leber's hereditary optic neuropathy (LHON) as the first maternally inherited disease associated with homoplasmic mtDNA mutations, we still struggle to achieve effective therapies. LHON is characterized by selective degeneration of retinal ganglion cells (RGCs) and is the most frequent mitochondrial disease, which leads young people to blindness, in particular males. Despite that causative mutations are present in all tissues, only a specific cell type is affected. Our deep understanding of the pathogenic mechanisms in LHON is hampered by the lack of appropriate models since investigations have been traditionally performed in non-neuronal cells. Effective in-vitro models of LHON are now emerging, casting promise to speed our understanding of pathophysiology and test therapeutic strategies to accelerate translation into clinic. We here review the potentials of these new models and their impact on the future of LHON patients.
Collapse
Affiliation(s)
- Camille Peron
- Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - Alessandra Maresca
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Programma di Neurogenetica, Bologna, Italy
| | - Andrea Cavaliere
- Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - Angelo Iannielli
- San Raffaele Scientific Institute, Milan, Italy.,National Research Council (CNR), Institute of Neuroscience, Milan, Italy
| | - Vania Broccoli
- San Raffaele Scientific Institute, Milan, Italy.,National Research Council (CNR), Institute of Neuroscience, Milan, Italy
| | - Valerio Carelli
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Programma di Neurogenetica, Bologna, Italy.,Department of Biomedical and Neuromotor Sciences-DIBINEM, University of Bologna, Bologna, Italy
| | - Ivano Di Meo
- Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - Valeria Tiranti
- Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| |
Collapse
|
8
|
Peron C, Mauceri R, Iannielli A, Cavaliere A, Legati A, Rizzo A, Sciacca FL, Broccoli V, Tiranti V. Generation of two human iPSC lines, FINCBi002-A and FINCBi003-A, carrying heteroplasmic macrodeletion of mitochondrial DNA causing Pearson's syndrome. Stem Cell Res 2021; 50:102151. [PMID: 33434818 DOI: 10.1016/j.scr.2020.102151] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/20/2020] [Revised: 12/03/2020] [Accepted: 12/30/2020] [Indexed: 11/26/2022] Open
Abstract
Pearson marrow pancreas syndrome (PMPS) is a sporadic mitochondrial disease, resulting from the clonal expansion of a mutated mitochondrial DNA (mtDNA) molecule bearing a macro-deletion, and therefore missing essential genetic information. PMPS is characterized by the presence of deleted (Δ) mtDNA that co-exist with the presence of a variable amount of wild-type mtDNA, a condition termed heteroplasmy. All tissues of the affected individual, including the haemopoietic system and the post-mitotic, highly specialized tissues (brain, skeletal muscle, and heart) contain the large-scale mtDNA deletion in variable amount. We generated human induced pluripotent stem cells (hiPSCs) from two PMPS patients, carrying different type of large-scale deletion.
Collapse
Affiliation(s)
- Camille Peron
- Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy
| | - Roberta Mauceri
- Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy
| | - Angelo Iannielli
- San Raffaele Scientific Institute, Milan, Italy; National Research Council (CNR), Institute of Neuroscience, Milan, Italy
| | - Andrea Cavaliere
- Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy
| | - Andrea Legati
- Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy
| | - Ambra Rizzo
- Laboratory of Clinical Investigation, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy
| | - Francesca L Sciacca
- Laboratory of Clinical Investigation, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy
| | - Vania Broccoli
- San Raffaele Scientific Institute, Milan, Italy; National Research Council (CNR), Institute of Neuroscience, Milan, Italy
| | - Valeria Tiranti
- Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy.
| |
Collapse
|
9
|
Delle Donne M, Iannielli A, Capozza P, De Caterina R, Marzilli M. Cardioprotective effect of Trimetazidine in patients with early breast cancer receiving anthracycline-based chemotherapy. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Anthracyclines, alone or in combination with other drugs, are among the most effective chemotherapeutic agents to treat breast cancer both in the adjuvant and neoadjuvant settings. Unfortunately, anthracycline-associated dose-dependent cardiotoxicity is a limiting factor in clinical use. Extensive efforts have been devoted to identifying strategies to prevent anthracycline-induced cardiotoxicity. However, most cardioprotective agents have shown little efficacy in clinical trials. We hypothesized that myocardial damage by anthracyclines could be rationally prevented by using trimetazidine (TMZ), previously reported to interfere with anthracycline- and trastuzumab-induced cardiotoxicity. Therefore, we planned a randomized, controlled, open trial to determine whether TMZ may prevent the development of left ventricular (LV) dysfunction in patients receiving standard treatment for breast cancer.
Methods
The trial included 73 patients (41.2±8.1 years) undergoing surgery for breast cancer, who were scheduled for adjuvant epirubicin-containing chemotherapy and, if indicated, trastuzumab. Patients were randomly allocated in a 1:1 ratio to receive TMZ or baseline therapy only (control group). The main study endpoint was a reduction in the deterioration of left ventricular ejection fraction (LVEF), as evaluated by serial echocardiography performed at randomization and then every 3 months after the start of chemotherapy and for 1 year after its completion. Secondary outcome measures included echocardiographic indices of LV diastolic dysfunction, structural myocardial alterations, as assessed by speckle tracking echocardiography, and changes in cardiac biomarkers (troponin and brain natriuretic peptide).
Results
We found no significant differences between the two groups regarding baseline clinical and echocardiographic parameters. The two groups reached a similar cumulative dose of doxorubicin. No patient died during the study and no patients withdrew from chemotherapy. Three months after the start of chemotherapy, nonsignificant changes were observed in LVEF, shortening fraction, and LV diameters. No significant changes in cardiac biomarkers were observed in either group. Tissue Doppler imaging detected a significant decrease in myocardial velocities (P=0.001) in the control group, indicating LV diastolic dysfunction. In the same group, speckle tracking imaging revealed a statistically significant alteration in ventricular deformation (P=0.01), which means a decrease in LV systolic function. In the TMZ group, no significant alterations in LV diastolic function were observed.
Conclusions
Tissue Doppler imaging and speckle tracking imaging are more sensitive than conventional echocardiograms in the early diagnosis of cardiac dysfunction and TMZ seems to have an important role in the prevention of cardiotoxicity.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- M.G Delle Donne
- University of Pisa, Department of Surgery, Medical, Molecular and Critical Area Pathology, Pisa, Italy
| | | | - P Capozza
- University of Pisa, Department of Surgery, Medical, Molecular and Critical Area Pathology, Pisa, Italy
| | - R De Caterina
- University of Pisa, Department of Surgery, Medical, Molecular and Critical Area Pathology, Pisa, Italy
| | - M Marzilli
- University of Pisa, Department of Surgery, Medical, Molecular and Critical Area Pathology, Pisa, Italy
| |
Collapse
|
10
|
Iannielli A, Ugolini GS, Cordiglieri C, Bido S, Rubio A, Colasante G, Valtorta M, Cabassi T, Rasponi M, Broccoli V. Reconstitution of the Human Nigro-striatal Pathway on-a-Chip Reveals OPA1-Dependent Mitochondrial Defects and Loss of Dopaminergic Synapses. Cell Rep 2020; 29:4646-4656.e4. [PMID: 31875567 PMCID: PMC6941223 DOI: 10.1016/j.celrep.2019.11.111] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2019] [Revised: 10/26/2019] [Accepted: 11/26/2019] [Indexed: 01/06/2023] Open
Abstract
Stem cell-derived neurons are generally obtained in mass cultures that lack both spatial organization and any meaningful connectivity. We implement a microfluidic system for long-term culture of human neurons with patterned projections and synaptic terminals. Co-culture of human midbrain dopaminergic and striatal medium spiny neurons on the microchip establishes an orchestrated nigro-striatal circuitry with functional dopaminergic synapses. We use this platform to dissect the mitochondrial dysfunctions associated with a genetic form of Parkinson’s disease (PD) with OPA1 mutations. Remarkably, we find that axons of OPA1 mutant dopaminergic neurons exhibit a significant reduction of mitochondrial mass. This defect causes a significant loss of dopaminergic synapses, which worsens in long-term cultures. Therefore, PD-associated depletion of mitochondria at synapses might precede loss of neuronal connectivity and neurodegeneration. In vitro reconstitution of human circuitries by microfluidic technology offers a powerful system to study brain networks by establishing ordered neuronal compartments and correct synapse identity. Long-term stable reconstitution of the human nigro-striatal neuronal circuit on-a-chip Stable synaptic connectivity of the iPSC-derived nigro-striatal neuronal connections Dopaminergic-specific synaptic identity of the iPSC-derived nigro-striatal pathway PD-OPA1 DA axons show a severe loss and impairment of mitochondria
Collapse
Affiliation(s)
- Angelo Iannielli
- Stem Cell and Neurogenesis Unit, Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy; CNR Institute of Neuroscience, 20129 Milan, Italy
| | - Giovanni Stefano Ugolini
- Department of Electronics, Information & Bioengineering, Politecnico di Milano, 20133 Milan, Italy
| | - Chiara Cordiglieri
- National Institute of Molecular Genetics "Romeo e Enrica Invernizzi" - INGM, 20122 Milan, Italy
| | - Simone Bido
- Stem Cell and Neurogenesis Unit, Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Alicia Rubio
- Stem Cell and Neurogenesis Unit, Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy; CNR Institute of Neuroscience, 20129 Milan, Italy
| | - Gaia Colasante
- Stem Cell and Neurogenesis Unit, Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Marco Valtorta
- Stem Cell and Neurogenesis Unit, Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy; CNR Institute of Neuroscience, 20129 Milan, Italy
| | - Tommaso Cabassi
- Stem Cell and Neurogenesis Unit, Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Marco Rasponi
- Department of Electronics, Information & Bioengineering, Politecnico di Milano, 20133 Milan, Italy
| | - Vania Broccoli
- Stem Cell and Neurogenesis Unit, Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy; CNR Institute of Neuroscience, 20129 Milan, Italy.
| |
Collapse
|
11
|
Mazzara PG, Muggeo S, Luoni M, Massimino L, Zaghi M, Valverde PTT, Brusco S, Marzi MJ, Palma C, Colasante G, Iannielli A, Paulis M, Cordiglieri C, Giannelli SG, Podini P, Gellera C, Taroni F, Nicassio F, Rasponi M, Broccoli V. Frataxin gene editing rescues Friedreich's ataxia pathology in dorsal root ganglia organoid-derived sensory neurons. Nat Commun 2020; 11:4178. [PMID: 32826895 PMCID: PMC7442818 DOI: 10.1038/s41467-020-17954-3] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2019] [Accepted: 07/28/2020] [Indexed: 12/31/2022] Open
Abstract
Friedreich's ataxia (FRDA) is an autosomal-recessive neurodegenerative and cardiac disorder which occurs when transcription of the FXN gene is silenced due to an excessive expansion of GAA repeats into its first intron. Herein, we generate dorsal root ganglia organoids (DRG organoids) by in vitro differentiation of human iPSCs. Bulk and single-cell RNA sequencing show that DRG organoids present a transcriptional signature similar to native DRGs and display the main peripheral sensory neuronal and glial cell subtypes. Furthermore, when co-cultured with human intrafusal muscle fibers, DRG organoid sensory neurons contact their peripheral targets and reconstitute the muscle spindle proprioceptive receptors. FRDA DRG organoids model some molecular and cellular deficits of the disease that are rescued when the entire FXN intron 1 is removed, and not with the excision of the expanded GAA tract. These results strongly suggest that removal of the repressed chromatin flanking the GAA tract might contribute to rescue FXN total expression and fully revert the pathological hallmarks of FRDA DRG neurons.
Collapse
Affiliation(s)
- Pietro Giuseppe Mazzara
- Division of Neuroscience, San Raffaele Scientific Institute, 20132, Milan, Italy
- Department of Neuroscience, The Scripps Research Institute, 92037, La Jolla, CA, USA
| | - Sharon Muggeo
- Division of Neuroscience, San Raffaele Scientific Institute, 20132, Milan, Italy
| | - Mirko Luoni
- Division of Neuroscience, San Raffaele Scientific Institute, 20132, Milan, Italy
| | - Luca Massimino
- Division of Neuroscience, San Raffaele Scientific Institute, 20132, Milan, Italy
| | - Mattia Zaghi
- Division of Neuroscience, San Raffaele Scientific Institute, 20132, Milan, Italy
| | | | - Simone Brusco
- Division of Neuroscience, San Raffaele Scientific Institute, 20132, Milan, Italy
| | - Matteo Jacopo Marzi
- Center for Genomic Science of IIT@SEMM, Istituto Italiano di Tecnologia (IIT), 20139, Milan, Italy
| | - Cecilia Palma
- Department of Electronics, Information & Bioengineering, Politecnico di Milano, 20133, Milan, Italy
| | - Gaia Colasante
- Division of Neuroscience, San Raffaele Scientific Institute, 20132, Milan, Italy
| | - Angelo Iannielli
- Division of Neuroscience, San Raffaele Scientific Institute, 20132, Milan, Italy
- National Research Council (CNR), Institute of Neuroscience, 20129, Milan, Italy
| | - Marianna Paulis
- Humanitas Clinical and Research Center, 20089, Rozzano, Milano, Italy
| | - Chiara Cordiglieri
- National Institute of Molecular Genetics "Romeo e Enrica Invernizzi" - INGM, 20122, Milan, Italy
| | - Serena Gea Giannelli
- Division of Neuroscience, San Raffaele Scientific Institute, 20132, Milan, Italy
| | - Paola Podini
- Division of Neuroscience, San Raffaele Scientific Institute, 20132, Milan, Italy
| | - Cinzia Gellera
- Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133, Milan, Italy
| | - Franco Taroni
- Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133, Milan, Italy
| | - Francesco Nicassio
- Center for Genomic Science of IIT@SEMM, Istituto Italiano di Tecnologia (IIT), 20139, Milan, Italy
| | - Marco Rasponi
- Department of Electronics, Information & Bioengineering, Politecnico di Milano, 20133, Milan, Italy
| | - Vania Broccoli
- Division of Neuroscience, San Raffaele Scientific Institute, 20132, Milan, Italy.
- National Research Council (CNR), Institute of Neuroscience, 20129, Milan, Italy.
| |
Collapse
|
12
|
Luoni M, Giannelli S, Indrigo MT, Niro A, Massimino L, Iannielli A, Passeri L, Russo F, Morabito G, Calamita P, Gregori S, Deverman B, Broccoli V. Whole brain delivery of an instability-prone Mecp2 transgene improves behavioral and molecular pathological defects in mouse models of Rett syndrome. eLife 2020; 9:52629. [PMID: 32207685 PMCID: PMC7117907 DOI: 10.7554/elife.52629] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Accepted: 03/23/2020] [Indexed: 12/29/2022] Open
Abstract
Rett syndrome is an incurable neurodevelopmental disorder caused by mutations in the gene encoding for methyl-CpG binding-protein 2 (MeCP2). Gene therapy for this disease presents inherent hurdles since MECP2 is expressed throughout the brain and its duplication leads to severe neurological conditions as well. Herein, we use the AAV-PHP.eB to deliver an instability-prone Mecp2 (iMecp2) transgene cassette which, increasing RNA destabilization and inefficient protein translation of the viral Mecp2 transgene, limits supraphysiological Mecp2 protein levels. Intravenous injections of the PHP.eB-iMecp2 virus in symptomatic Mecp2 mutant mice significantly improved locomotor activity, lifespan and gene expression normalization. Remarkably, PHP.eB-iMecp2 administration was well tolerated in female Mecp2 mutant or in wild-type animals. In contrast, we observed a strong immune response to the transgene in treated male Mecp2 mutant mice that was overcome by immunosuppression. Overall, PHP.eB-mediated delivery of iMecp2 provided widespread and efficient gene transfer maintaining physiological Mecp2 protein levels in the brain.
Collapse
Affiliation(s)
- Mirko Luoni
- Stem Cell and Neurogenesis Unit, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.,CNR Institute of Neuroscience, Milan, Italy
| | - Serena Giannelli
- Stem Cell and Neurogenesis Unit, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy
| | - Marzia Tina Indrigo
- Stem Cell and Neurogenesis Unit, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy
| | - Antonio Niro
- Stem Cell and Neurogenesis Unit, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.,CNR Institute of Neuroscience, Milan, Italy
| | - Luca Massimino
- Stem Cell and Neurogenesis Unit, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy
| | - Angelo Iannielli
- Stem Cell and Neurogenesis Unit, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.,CNR Institute of Neuroscience, Milan, Italy
| | - Laura Passeri
- San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), San Raffaele Scientific Institute IRCCS, Via Olgettina, Milan, Italy
| | - Fabio Russo
- San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), San Raffaele Scientific Institute IRCCS, Via Olgettina, Milan, Italy
| | - Giuseppe Morabito
- Stem Cell and Neurogenesis Unit, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy
| | - Piera Calamita
- National Institute of Molecular Genetics (INGM), Milan, Italy
| | - Silvia Gregori
- San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), San Raffaele Scientific Institute IRCCS, Via Olgettina, Milan, Italy
| | - Benjamin Deverman
- Stanley Center for Psychiatric Research at Broad Institute, Cambridge, United States
| | - Vania Broccoli
- Stem Cell and Neurogenesis Unit, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.,CNR Institute of Neuroscience, Milan, Italy
| |
Collapse
|
13
|
Iannielli A, Bido S, Folladori L, Segnali A, Cancellieri C, Maresca A, Massimino L, Rubio A, Morabito G, Caporali L, Tagliavini F, Musumeci O, Gregato G, Bezard E, Carelli V, Tiranti V, Broccoli V. Pharmacological Inhibition of Necroptosis Protects from Dopaminergic Neuronal Cell Death in Parkinson's Disease Models. Cell Rep 2019; 22:2066-2079. [PMID: 29466734 PMCID: PMC5842028 DOI: 10.1016/j.celrep.2018.01.089] [Citation(s) in RCA: 151] [Impact Index Per Article: 30.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Revised: 12/13/2017] [Accepted: 01/29/2018] [Indexed: 12/21/2022] Open
Abstract
Dysfunctions in mitochondrial dynamics and metabolism are common pathological processes associated with Parkinson’s disease (PD). It was recently shown that an inherited form of PD and dementia is caused by mutations in the OPA1 gene, which encodes for a key player in mitochondrial fusion and structure. iPSC-derived neural cells from these patients exhibited severe mitochondrial fragmentation, respiration impairment, ATP deficits, and heightened oxidative stress. Reconstitution of normal levels of OPA1 in PD-derived neural cells normalized mitochondria morphology and function. OPA1-mutated neuronal cultures showed reduced survival in vitro. Intriguingly, selective inhibition of necroptosis effectively rescued this survival deficit. Additionally, dampening necroptosis in MPTP-treated mice protected from DA neuronal cell loss. This human iPSC-based model captures both early pathological events in OPA1 mutant neural cells and the beneficial effects of blocking necroptosis, highlighting this cell death process as a potential therapeutic target for PD. OPA1 mutant iPSC-derived NPCs contain dysfunctional mitochondria OPA1 mutant iPSC-derived NPCs present high levels of oxidative stress Nec-1s can improve survival of OPA1 mutant human neurons in vitro Nec-1s counteracts the dopaminergic cell loss in MPTP-treated neurons
Collapse
Affiliation(s)
- Angelo Iannielli
- Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Simone Bido
- Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Lucrezia Folladori
- Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Alice Segnali
- Molecular Neurogenetics Unit, IRCCS Foundation C. Besta Neurological Institute, 20126 Milan, Italy
| | - Cinzia Cancellieri
- Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Alessandra Maresca
- IRCCS Institute of Neurological Sciences of Bologna, Bellaria Hospital, Bologna, Italy
| | - Luca Massimino
- University of Milano-Bicocca, Department of Medicine and Surgery, Monza, Italy
| | - Alicia Rubio
- Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy; National Research Council (CNR), Institute of Neuroscience, 20129 Milan, Italy
| | - Giuseppe Morabito
- Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy; University of Milano-Bicocca, Milan, Italy
| | - Leonardo Caporali
- IRCCS Institute of Neurological Sciences of Bologna, Bellaria Hospital, Bologna, Italy
| | - Francesca Tagliavini
- IRCCS Institute of Neurological Sciences of Bologna, Bellaria Hospital, Bologna, Italy
| | - Olimpia Musumeci
- Department of Neuroscience, University of Messina, Messina, Italy
| | - Giuliana Gregato
- Division of Clinical Haematology-Oncology, European Institute of Oncology, Milan, Italy
| | - Erwan Bezard
- Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - Valerio Carelli
- IRCCS Institute of Neurological Sciences of Bologna, Bellaria Hospital, Bologna, Italy; Neurology Unit, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
| | - Valeria Tiranti
- Molecular Neurogenetics Unit, IRCCS Foundation C. Besta Neurological Institute, 20126 Milan, Italy
| | - Vania Broccoli
- Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy; National Research Council (CNR), Institute of Neuroscience, 20129 Milan, Italy.
| |
Collapse
|
14
|
Rubio A, Luoni M, Giannelli SG, Radice I, Iannielli A, Cancellieri C, Di Berardino C, Regalia G, Lazzari G, Menegon A, Taverna S, Broccoli V. Rapid and efficient CRISPR/Cas9 gene inactivation in human neurons during human pluripotent stem cell differentiation and direct reprogramming. Sci Rep 2016; 6:37540. [PMID: 27857203 PMCID: PMC5114606 DOI: 10.1038/srep37540] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2016] [Accepted: 10/31/2016] [Indexed: 12/15/2022] Open
Abstract
The CRISPR/Cas9 system is a rapid and customizable tool for gene editing in mammalian cells. In particular, this approach has widely opened new opportunities for genetic studies in neurological disease. Human neurons can be differentiated in vitro from hPSC (human Pluripotent Stem Cells), hNPCs (human Neural Precursor Cells) or even directly reprogrammed from fibroblasts. Here, we described a new platform which enables, rapid and efficient CRISPR/Cas9-mediated genome targeting simultaneously with three different paradigms for in vitro generation of neurons. This system was employed to inactivate two genes associated with neurological disorder (TSC2 and KCNQ2) and achieved up to 85% efficiency of gene targeting in the differentiated cells. In particular, we devised a protocol that, combining the expression of the CRISPR components with neurogenic factors, generated functional human neurons highly enriched for the desired genome modification in only 5 weeks. This new approach is easy, fast and that does not require the generation of stable isogenic clones, practice that is time consuming and for some genes not feasible.
Collapse
Affiliation(s)
- Alicia Rubio
- Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Mirko Luoni
- Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Serena G. Giannelli
- Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Isabella Radice
- Advanced Light and Electron Microscopy Bio-Imaging Centre, Experimental Imaging Centre, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Angelo Iannielli
- Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Cinzia Cancellieri
- Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
| | | | - Giulia Regalia
- Advanced Light and Electron Microscopy Bio-Imaging Centre, Experimental Imaging Centre, San Raffaele Scientific Institute, 20132 Milan, Italy
- Neuroengineering and medical robotics laboratory, Department of Electronics, Information and Bioengineering, Politecnico di Milano, 20133 Milan, Italy
| | - Giovanna Lazzari
- Avantea srl, Laboratory of Reproductive Technologies, Via Porcellasco 7f, 26100 Cremona, Fondazione Avantea, Cremona
| | - Andrea Menegon
- Advanced Light and Electron Microscopy Bio-Imaging Centre, Experimental Imaging Centre, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Stefano Taverna
- Neuroimmunology Unit, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Vania Broccoli
- Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
- National Research Council (CNR), Institute of Neuroscience, Milan, Italy
| |
Collapse
|
15
|
Gautier CA, Erpapazoglou Z, Mouton-Liger F, Muriel MP, Cormier F, Bigou S, Duffaure S, Girard M, Foret B, Iannielli A, Broccoli V, Dalle C, Bohl D, Michel PP, Corvol JC, Brice A, Corti O. The endoplasmic reticulum-mitochondria interface is perturbed in PARK2 knockout mice and patients with PARK2 mutations. Hum Mol Genet 2016; 25:2972-2984. [PMID: 27206984 DOI: 10.1093/hmg/ddw148] [Citation(s) in RCA: 72] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2016] [Revised: 05/10/2016] [Accepted: 05/10/2016] [Indexed: 12/13/2022] Open
Abstract
Mutations in PARK2, encoding the E3 ubiquitin protein ligase Parkin, are a common cause of autosomal recessive Parkinson's disease (PD). Loss of PARK2 function compromises mitochondrial quality by affecting mitochondrial biogenesis, bioenergetics, dynamics, transport and turnover. We investigated the impact of PARK2 dysfunction on the endoplasmic reticulum (ER)-mitochondria interface, which mediates calcium (Ca2+) exchange between the two compartments and is essential for Parkin-dependent mitophagy. Confocal and electron microscopy analyses showed the ER and mitochondria to be in closer proximity in primary fibroblasts from PARK2 knockout (KO) mice and PD patients with PARK2 mutations than in controls. Ca2+ flux to the cytosol was also modified, due to enhanced ER-to-mitochondria Ca2+ transfers, a change that was also observed in neurons derived from induced pluripotent stem cells of a patient with PARK2 mutations. Subcellular fractionation showed the abundance of the Parkin substrate mitofusin 2 (Mfn2), which is known to modulate the ER-mitochondria interface, to be specifically higher in the mitochondrion-associated ER membrane compartment in PARK2 KO tissue. Mfn2 downregulation or the exogenous expression of normal Parkin restored cytosolic Ca2+ transients in fibroblasts from patients with PARK2 mutations. In contrast, a catalytically inactive PD-related Parkin variant had no effect. Overall, our data suggest that Parkin is directly involved in regulating ER-mitochondria contacts and provide new insight into the role of the loss of Parkin function in PD development.
Collapse
Affiliation(s)
- Clément A Gautier
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Inserm, U1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, CNRS, UMR 7225, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Institut du Cerveau et de la Moelle épinière, ICM, F-75013 Paris, France
| | - Zoi Erpapazoglou
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Inserm, U1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, CNRS, UMR 7225, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Institut du Cerveau et de la Moelle épinière, ICM, F-75013 Paris, France
| | - François Mouton-Liger
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Inserm, U1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, CNRS, UMR 7225, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Institut du Cerveau et de la Moelle épinière, ICM, F-75013 Paris, France
| | - Marie Paule Muriel
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Inserm, U1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, CNRS, UMR 7225, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Institut du Cerveau et de la Moelle épinière, ICM, F-75013 Paris, France
| | - Florence Cormier
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Inserm, U1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, CNRS, UMR 7225, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Institut du Cerveau et de la Moelle épinière, ICM, F-75013 Paris, France
- National Research Council (CNR), Institute of Neuroscience, Milan, Italy
| | - Stéphanie Bigou
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Inserm, U1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, CNRS, UMR 7225, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Institut du Cerveau et de la Moelle épinière, ICM, F-75013 Paris, France
| | - Sophie Duffaure
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Inserm, U1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, CNRS, UMR 7225, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Institut du Cerveau et de la Moelle épinière, ICM, F-75013 Paris, France
| | - Mathilde Girard
- CECS, I-Stem, AFM, Institute of Stem Cell Therapy and Exploration of Monogenic Diseases, 91030 Evry cedex, France
| | - Benjamin Foret
- CECS, I-Stem, AFM, Institute of Stem Cell Therapy and Exploration of Monogenic Diseases, 91030 Evry cedex, France
| | - Angelo Iannielli
- National Research Council (CNR), Institute of Neuroscience, Milan, Italy
- Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Vania Broccoli
- National Research Council (CNR), Institute of Neuroscience, Milan, Italy
- Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Carine Dalle
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Inserm, U1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, CNRS, UMR 7225, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Institut du Cerveau et de la Moelle épinière, ICM, F-75013 Paris, France
| | - Delphine Bohl
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Inserm, U1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, CNRS, UMR 7225, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Institut du Cerveau et de la Moelle épinière, ICM, F-75013 Paris, France
| | - Patrick P Michel
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Inserm, U1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, CNRS, UMR 7225, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Institut du Cerveau et de la Moelle épinière, ICM, F-75013 Paris, France
| | - Jean-Christophe Corvol
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Inserm, U1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, CNRS, UMR 7225, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Institut du Cerveau et de la Moelle épinière, ICM, F-75013 Paris, France
- Assistance-publique Hôpitaux de Paris, Inserm, CIC-1422, Department of Neurology, Hôpital Pitié-Salpêtrière, F-75013 Paris, France
| | - Alexis Brice
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Inserm, U1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, CNRS, UMR 7225, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Institut du Cerveau et de la Moelle épinière, ICM, F-75013 Paris, France
| | - Olga Corti
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Inserm, U1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, CNRS, UMR 7225, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, F-75013 Paris, France
- Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives, Institut du Cerveau et de la Moelle épinière, ICM, F-75013 Paris, France
| |
Collapse
|
16
|
Bovetti S, Bonzano S, Garzotto D, Giannelli SG, Iannielli A, Armentano M, Studer M, De Marchis S. COUP-TFI controls activity-dependent tyrosine hydroxylase expression in adult dopaminergic olfactory bulb interneurons. Development 2013; 140:4850-9. [DOI: 10.1242/dev.089961] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
COUP-TFI is an orphan nuclear receptor acting as a strong transcriptional regulator in different aspects of forebrain embryonic development. In this study, we investigated COUP-TFI expression and function in the mouse olfactory bulb (OB), a highly plastic telencephalic region in which continuous integration of newly generated inhibitory interneurons occurs throughout life. OB interneurons belong to different populations that originate from distinct progenitor lineages. Here, we show that COUP-TFI is highly expressed in tyrosine hydroxylase (TH)-positive dopaminergic interneurons in the adult OB glomerular layer (GL). We found that odour deprivation, which is known to downregulate TH expression in the OB, also downregulates COUP-TFI in dopaminergic cells, indicating a possible correlation between TH- and COUP-TFI-activity-dependent action. Moreover, we demonstrate that conditional inactivation of COUP-TFI in the EMX1 lineage results in a significant reduction of both TH and ZIF268 expression in the GL. Finally, lentiviral vector-mediated COUP-TFI deletion in adult-generated interneurons confirmed that COUP-TFI acts cell-autonomously in the control of TH and ZIF268 expression. These data indicate that COUP-TFI regulates TH expression in OB cells through an activity-dependent mechanism involving ZIF268 induction and strongly argue for a maintenance rather than establishment function of COUP-TFI in dopaminergic commitment. Our study reveals a previously unknown role for COUP-TFI in the adult brain as a key regulator in the control of sensory-dependent plasticity in olfactory dopaminergic neurons.
Collapse
Affiliation(s)
- Serena Bovetti
- Department of Life Sciences and Systems Biology, University of Turin, Via Accademia Albertina 13, 10123, Torino, Italy
| | - Sara Bonzano
- Department of Life Sciences and Systems Biology, University of Turin, Via Accademia Albertina 13, 10123, Torino, Italy
- Neuroscience Institute Cavalieri Ottolenghi (NICO), Regione Gerzole 10, 10043, Orbassano, Italy
| | - Donatella Garzotto
- Department of Life Sciences and Systems Biology, University of Turin, Via Accademia Albertina 13, 10123, Torino, Italy
| | - Serena Gea Giannelli
- San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Division of Regenerative Medicine, Stem Cells, and Gene Therapy, San Raffaele Scientific Institute, Via Olgettina28, 20132, Milano, Italy
| | - Angelo Iannielli
- Department of Life Sciences and Systems Biology, University of Turin, Via Accademia Albertina 13, 10123, Torino, Italy
- Neuroscience Institute Cavalieri Ottolenghi (NICO), Regione Gerzole 10, 10043, Orbassano, Italy
| | - Maria Armentano
- Neuroscience Institute Cavalieri Ottolenghi (NICO), Regione Gerzole 10, 10043, Orbassano, Italy
- Telethon Institute of Genetics and Medicine (TIGEM), Via P. Castellino 111, 80131, Napoli, Italy
| | - Michèle Studer
- Telethon Institute of Genetics and Medicine (TIGEM), Via P. Castellino 111, 80131, Napoli, Italy
- University of Nice Sophia-Antipolis, Parc Valrose, 28 Avenue Valrose, F-06108 Nice, France
- INSERM UMR 1091, Parc Valrose, 28 Avenue Valrose, F-06108 Nice, France
| | - Silvia De Marchis
- Department of Life Sciences and Systems Biology, University of Turin, Via Accademia Albertina 13, 10123, Torino, Italy
- Neuroscience Institute Cavalieri Ottolenghi (NICO), Regione Gerzole 10, 10043, Orbassano, Italy
| |
Collapse
|